Cinvanti™ (aprepitant) – New drug approval
November 9, 2017 – Heron Therapeutics announced the FDA approval of Cinvanti (aprepitant) for use in combination with other antiemetic agents in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin, and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
Top